| 1 |
Xu L, Sgalla G, Wang F, Zhu M, Li L, Li P, Xie Q, Lv X, Yu J, Wang G, Wan H, Richeldi L, Luo F. Monitoring small airway dysfunction in connective tissue disease-related interstitial lung disease: a retrospective and prospective study. BMC Pulm Med 2023;23:90. [PMID: 36941622 DOI: 10.1186/s12890-023-02381-z] [Reference Citation Analysis]
|
| 2 |
Matson SM, Demoruelle MK. Connective Tissue Disease Associated Interstitial Lung Disease. Immunology and Allergy Clinics of North America 2023. [DOI: 10.1016/j.iac.2023.01.005] [Reference Citation Analysis]
|
| 3 |
Chrysanthopoulou A, Antoniadou C, Natsi AM, Gavriilidis E, Papadopoulos V, Xingi E, Didaskalou S, Mikroulis D, Tsironidou V, Kambas K, Koffa M, Skendros P, Ritis K. Down-regulation of KLF2 in lung fibroblasts is linked with COVID-19 immunofibrosis and restored by combined inhibition of NETs, JAK-1/2 and IL-6 signaling. Clin Immunol 2023;247:109240. [PMID: 36693535 DOI: 10.1016/j.clim.2023.109240] [Reference Citation Analysis]
|
| 4 |
Cerro Chiang G, Parimon T. Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers. Int J Mol Sci 2023;24. [PMID: 36768729 DOI: 10.3390/ijms24032405] [Reference Citation Analysis]
|
| 5 |
龚 玲. Research Progress of Biologics and Antifibrosis Therapy in Children with Connective Tissue Disease-Associated Interstitial Lung Disease. ACM 2023;13:2305-2312. [DOI: 10.12677/acm.2023.132322] [Reference Citation Analysis]
|
| 6 |
Wu D, Luo Y, Li T, Zhao X, Lv T, Fang G, Ou P, Li H, Luo X, Huang A, Pang Y. Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment. Front Immunol 2022;13:1051082. [PMID: 36618407 DOI: 10.3389/fimmu.2022.1051082] [Reference Citation Analysis]
|
| 7 |
Radić M, Novak S, Barešić M, Hećimović A, Perković D, Tekavec-Trkanjec J, Mayer M, Prus V, Morović-Vergles J, Marasović Krstulović D, Cerovec M, Bulat Kardum L, Samaržija M, Anić B. Delphi-Based Consensus on Interstitial Lung Disease Screening in Patients with Connective Tissue Diseases (Croatian National-Based Study). Biomedicines 2022;10. [PMID: 36552047 DOI: 10.3390/biomedicines10123291] [Reference Citation Analysis]
|
| 8 |
Lu M, Gong L, Huang C, Ye M, Wang H, Liu Y, Liu D. Analysis of Clinical Characteristics of Connective Tissue Disease-Associated Interstitial Lung Disease in 161 Patients: A Retrospective Study. Int J Gen Med 2022;15:8617-25. [PMID: 36545245 DOI: 10.2147/IJGM.S391146] [Reference Citation Analysis]
|
| 9 |
Liu Y, Lu F, Li X, Yang Y, Yang J. The silencing of lnc-NONHSAT071210 suppresses the proliferation, fibrosis, migration, and invasion of TGFβ1-treated lung epithelial cells. Ann Transl Med 2022;10:1239. [PMID: 36544683 DOI: 10.21037/atm-22-5223] [Reference Citation Analysis]
|
| 10 |
Spagnolo P, Tonelli R, Samarelli AV, Castelli G, Cocconcelli E, Petrarulo S, Cerri S, Bernardinello N, Clini E, Saetta M, Balestro E. The role of immune response in the pathogenesis of idiopathic pulmonary fibrosis: far beyond the Th1/Th2 imbalance. Expert Opin Ther Targets 2022. [PMID: 35983984 DOI: 10.1080/14728222.2022.2114897] [Reference Citation Analysis]
|
| 11 |
Liossis SC, Bounia CA. Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion. Front Med 2022;9:937561. [DOI: 10.3389/fmed.2022.937561] [Reference Citation Analysis]
|
| 12 |
Palmucci S, Galioto F, Fazio G, Ferlito A, Cancemi G, Di Mari A, Sambataro G, Sambataro D, Zanframundo G, Mauro LA, Foti PV, Vancheri C, Basile A. Clinical and radiological features of lung disorders related to connective-tissue diseases: a pictorial essay. Insights Imaging 2022;13:108. [PMID: 35767157 DOI: 10.1186/s13244-022-01243-2] [Reference Citation Analysis]
|
| 13 |
Yeh JJ, Syue SH, Sun YF, Yeh YT, Zheng YC, Lin CL, Hsu CY, Kao CH. Hydroxychloroquine on the Pulmonary Vascular Diseases in Interstitial Lung Disease: Immunologic Effects, and Virus Interplay. Biomedicines 2022;10. [PMID: 35740313 DOI: 10.3390/biomedicines10061290] [Reference Citation Analysis]
|
| 14 |
Guiot J, Henket M, Frix A, Gester F, Thys M, Giltay L, Desir C, Moermans C, Njock M, Meunier P, Corhay J, Louis R. Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype ? Respir Res 2022;23. [DOI: 10.1186/s12931-022-02006-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 15 |
Huo R, Guo Q, Hu J, Li N, Gao R, Mi L, Zhang Z, Liu H, Guo Z, Zhao H, Zhang L, Xu K. Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease. DDDT 2022;Volume 16:991-998. [DOI: 10.2147/dddt.s353494] [Reference Citation Analysis]
|
| 16 |
Lillehoj EP, Luzina IG, Atamas SP. Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond. Front Immunol 2022;13:883079. [PMID: 35479093 DOI: 10.3389/fimmu.2022.883079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Sese DGA, Highland KB. Connective Tissue Disease, Interstitial Lung Disease, and Pulmonary Hypertension (CTD PH-ILD): A Distinct Entity and Potential Opportunity. Advances in Pulmonary Hypertension 2021;20:109-118. [DOI: 10.21693/1933-088x-20.4.109] [Reference Citation Analysis]
|
